Rislenemdaz - Cerecor

Drug Profile

Rislenemdaz - Cerecor

Alternative Names: CERC-301; MK-0657

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Cerecor; Merck & Co
  • Class Amines; Antihypotensives; Antiparkinsonians; Esters; Piperidines; Pyrimidines
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Phase I Parkinson's disease

Most Recent Events

  • 01 Aug 2018 Phase-I clinical trials in Parkinson's disease in USA (PO)
  • 11 May 2018 Cerecor plans to dose the first patient in a phase I trial for neurogenic orthostatic hypotension associated with Parkinson's disease in USA in the second quarter of 2018
  • 01 Mar 2018 US FDA approves IND application for rislenemdaz in neurogenic orthostatic hypotension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top